

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. – 53. (Cancelled).

54. (New) A compound which is 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-methyl-nicotinamide or a pharmaceutically acceptable salt or solvate thereof.

55. (New) A compound according to claim 54 which is an acid addition salt of 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-methyl-nicotinamide formed from a pharmaceutically acceptable acid selected from the group consisting of maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, sulphate, citric, lactic, mandelic, tartaric and methanesulphonic acid.

56. (New) A compound according to claim 55 which is an acid addition salt of 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1*H*-benzo[*d*]azepin-7-yloxy)-*N*-methyl-nicotinamide formed from hydrochloric acid.

57. (New) A pharmaceutical composition which comprises a compound as defined in claim 54 and a pharmaceutically acceptable carrier or excipient.

58. (New) A method of treatment of a neurological disease which comprises administering to a host in need thereof an effective amount of a compound as defined in claim 54.